https://news.augustaheadlines.com/story/540070/how-to-choose-the-right-portable-camping-power-bank-for-your-outdoor-adventures.html 2025-10-10T10:50:04+00:00 daily 1.0 https://news.augustaheadlines.com/story/540064/clostridium-difficile-infections-pipeline-2025-latest-fda-approvals-clinical-trials-and-emerging-therapies-assessment-by-delveinsight-novartis-ag-astellas-pharma-eli-lilly-company-astrazeneca.html 2025-10-10T10:32:02+00:00 daily 1.0 https://news.augustaheadlines.com/story/540056/cell-and-gene-therapies-in-rare-disorders-market-to-evolve-rapidly-over-the-next-decade-by-2034-delveinsight-observes-regenxbio-coave-therapeutics-gensight-biologics-ultragenyx-pfizer-sangamo.html 2025-10-10T09:54:03+00:00 daily 1.0 https://news.augustaheadlines.com/story/540055/crueltyfarm-uncovering-the-truth-about-animal-agriculture-and-inspiring-a-global-movement-for-compassion-health-and-sustainability.html 2025-10-10T09:48:03+00:00 daily 1.0 https://news.augustaheadlines.com/story/540054/waka-flocka-flame-to-headline-nightly-college-tour-launch-in-austin.html 2025-10-10T09:34:02+00:00 daily 1.0 https://news.augustaheadlines.com/story/540053/lambert-eaton-myasthenic-syndrome-market-positioned-for-accelerated-development-through-2034-delveinsight-finds-jacobus-pharmaceutical-catalyst-pharmaceuticals.html 2025-10-10T09:32:02+00:00 daily 1.0 https://news.augustaheadlines.com/story/540052/migraine-pipeline-2025-comprehensive-clinical-trials-and-therapies-analysis-with-key-moa-and-roa-insights-glaxosmithkline-merck-co-inc-pfizer-bausch-health-amgen-abbvie-inc-astrazeneca.html 2025-10-10T08:48:03+00:00 daily 1.0 https://news.augustaheadlines.com/story/540051/freelance-platforms-market-forecast-to-reach-usd-1654-billion-by-2030-driven-by-digital-skills-demand-and-flexible-workforce-trend.html 2025-10-10T07:24:03+00:00 daily 1.0 https://news.augustaheadlines.com/story/540050/surprising-comparison-disney-vs-taylor-swift-concert-costs.html 2025-10-10T07:06:03+00:00 daily 1.0 https://news.augustaheadlines.com/story/540049/medicus-pharma-nasdaq-mdcx-nears-surgeryfree-breakthrough-in-oncology.html 2025-10-10T07:04:03+00:00 daily 1.0